$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2011 Form 10-K Financial Statement

#000104746912001243 Filed on February 22, 2012

Income Statement

Concept	2011	2010 Q4	2010
Revenue	$853.0K	$4.000M	$978.0K
YoY Change	-12.78%	-14.89%	-99.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.60M	$3.100M	$11.40M
YoY Change	1.75%	29.17%	-10.24%
% of Gross Profit
Research & Development	$41.46M	$9.300M	$40.25M
YoY Change	3.01%	1.09%	-21.16%
% of Gross Profit
Depreciation & Amortization	$1.464M	$460.0K	$1.933M
YoY Change	-24.26%	-9.8%	-21.52%
% of Gross Profit
Operating Expenses	$53.02M	$12.40M	$51.70M
YoY Change	2.54%	5.98%	-20.39%
Operating Profit	-$45.43M		-$36.90M
YoY Change	23.13%		-146.53%
Interest Expense	-$1.948M	-$500.0K	-$569.0K
YoY Change	242.36%	400.0%	163.43%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$47.40M	-$8.800M	-$37.50M
YoY Change	26.4%	25.71%	-147.41%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$47.40M	-$8.800M	-$37.50M
YoY Change	26.4%	25.71%	-147.41%
Net Earnings / Revenue	-5556.86%	-220.0%	-3834.36%
Basic Earnings Per Share	-$1.00		-$0.93
Diluted Earnings Per Share	-$1.00	-$7.333M	-$0.93
COMMON SHARES
Basic Shares Outstanding	47.20M shares		40.37M shares
Diluted Shares Outstanding	47.20M shares		40.37M shares

Balance Sheet

Concept	2011	2010 Q4	2010
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.70M	$51.00M	$51.00M
YoY Change	-22.16%	15.38%	15.38%
Cash & Equivalents	$30.10M	$31.31M	$31.30M
Short-Term Investments	$9.700M	$19.70M	$19.70M
Other Short-Term Assets	$600.0K	$400.0K	$400.0K
YoY Change	50.0%	0.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$0.00	$100.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$40.30M	$51.52M	$51.50M
YoY Change	-21.75%	15.52%	15.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.400M	$2.181M	$2.200M
YoY Change	-36.36%	-45.48%	-45.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$600.0K	$366.0K	$400.0K
YoY Change	50.0%	-8.5%	0.0%
Total Long-Term Assets	$2.000M	$2.547M	$2.600M
YoY Change	-23.08%	-40.77%	-39.53%
TOTAL ASSETS
Total Short-Term Assets	$40.30M	$51.52M	$51.50M
Total Long-Term Assets	$2.000M	$2.547M	$2.600M
Total Assets	$42.30M	$54.07M	$54.10M
YoY Change	-21.81%	10.57%	10.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.500M	$1.925M	$1.900M
YoY Change	84.21%	-51.88%	-52.5%
Accrued Expenses	$7.400M	$6.700M	$6.700M
YoY Change	10.45%	1.52%	1.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.200M	$3.500M	$3.500M
YoY Change	20.0%	169.23%	169.23%
Total Short-Term Liabilities	$15.10M	$16.74M	$16.70M
YoY Change	-9.58%	1.43%	1.21%
LONG-TERM LIABILITIES
Long-Term Debt	$12.40M	$11.70M	$11.70M
YoY Change	5.98%	1362.5%	1362.5%
Other Long-Term Liabilities	$0.00	$2.200M	$2.200M
YoY Change	-100.0%	-67.16%	-67.16%
Total Long-Term Liabilities	$12.40M	$13.85M	$13.90M
YoY Change	-10.79%	84.69%	85.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.10M	$16.74M	$16.70M
Total Long-Term Liabilities	$12.40M	$13.85M	$13.90M
Total Liabilities	$27.60M	$30.59M	$30.60M
YoY Change	-9.8%	27.45%	27.5%
SHAREHOLDERS EQUITY
Retained Earnings		-$351.1M
YoY Change
Common Stock		$374.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.80M	$23.48M	$23.50M
YoY Change
Total Liabilities & Shareholders Equity	$42.30M	$54.07M	$54.10M
YoY Change	-21.81%	10.57%	10.63%

Cashflow Statement

Concept	2011	2010 Q4	2010
OPERATING ACTIVITIES
Net Income	-$47.40M	-$8.800M	-$37.50M
YoY Change	26.4%	25.71%	-147.41%
Depreciation, Depletion And Amortization	$1.464M	$460.0K	$1.933M
YoY Change	-24.26%	-9.8%	-21.52%
Cash From Operating Activities	-$47.30M	-$8.210M	-$38.20M
YoY Change	23.82%	13.09%	42.48%
INVESTING ACTIVITIES
Capital Expenditures	$690.0K	-$30.00K	$136.0K
YoY Change	407.35%	-150.0%	-70.04%
Acquisitions
YoY Change
Other Investing Activities	$10.02M	-$460.0K	-$19.67M
YoY Change	-150.94%	-102.72%	-191.49%
Cash From Investing Activities	$9.330M	-$480.0K	-$19.80M
YoY Change	-147.12%	-102.82%	-194.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$27.58M		$23.53M
YoY Change	17.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	36.74M	5.100M	45.16M
YoY Change	-18.64%	-1442.11%	-2220.19%
NET CHANGE
Cash From Operating Activities	-47.30M	-8.210M	-38.20M
Cash From Investing Activities	9.330M	-480.0K	-19.80M
Cash From Financing Activities	36.74M	5.100M	45.16M
Net Change In Cash	-1.230M	-3.590M	-12.84M
YoY Change	-90.42%	-138.35%	62.74%
FREE CASH FLOW
Cash From Operating Activities	-$47.30M	-$8.210M	-$38.20M
Capital Expenditures	$690.0K	-$30.00K	$136.0K
Free Cash Flow	-$47.99M	-$8.180M	-$38.34M
YoY Change	25.18%	11.75%	40.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	23479000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-351050000	USD
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49539808	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1407000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	40286000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	561000	USD
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	9650000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30075000	USD
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2010Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42090205	shares
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42090205	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49539808	shares
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54067000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2010Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	374528000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	30588000	USD
CY2010Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13852000	USD
CY2010Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2159000	USD
CY2010Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	26000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16736000	USD
CY2010Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3333000	USD
CY2010Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4572000	USD
CY2010Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	201000	USD
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	4194000	USD
CY2010Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	2511000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1925000	USD
CY2010Q4	us-gaap	Assets Assets	54067000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	366000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2181000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	51520000	USD
CY2010Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	431000	USD
CY2010Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	11667000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	45156000	USD
CY2010Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	116000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	27550000	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12402000	USD
CY2011Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	12388000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	14000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15148000	USD
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	4234000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	12000	USD
CY2011Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	4594000	USD
CY2010Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19663000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31310000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42324000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	14774000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398430000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	413196000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2010Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	2841000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3467000	USD
CY2011Q4	us-gaap	Assets Assets	42324000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	631000	USD
CY2009	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	79088000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37467000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47380000	USD
CY2009	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-216000	USD
CY2010	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-569000	USD
CY2011	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1948000	USD
CY2009	us-gaap	Operating Income Loss OperatingIncomeLoss	79304000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-36898000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-45432000	USD
CY2009	us-gaap	Operating Expenses OperatingExpenses	64941000	USD
CY2009	us-gaap	Restructuring Charges RestructuringCharges	1236000	USD
CY2009	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12651000	USD
CY2009	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	51054000	USD
CY2009	snta	Total Revenues TotalRevenues	144245000	USD
CY2009	snta	Collaborative Revenues CollaborativeRevenues	144245000	USD
CY2009	snta	Cost Sharing Reimbursements CostSharingReimbursements	18544000	USD
CY2009	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	125701000	USD
CY2010	us-gaap	Operating Expenses OperatingExpenses	51701000	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	53016000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11449000	USD
CY2010	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	40252000	USD
CY2010	snta	Total Revenues TotalRevenues	14803000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11552000	USD
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41464000	USD
CY2011	snta	Total Revenues TotalRevenues	7584000	USD
CY2010	us-gaap	Revenue From Grants RevenueFromGrants	978000	USD
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	853000	USD
CY2010	snta	Collaborative Revenues CollaborativeRevenues	13825000	USD
CY2010	snta	Cost Sharing Reimbursements CostSharingReimbursements	9253000	USD
CY2011	snta	Collaborative Revenues CollaborativeRevenues	6731000	USD
CY2010	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	4572000	USD
CY2011	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	6731000	USD
CY2011	us-gaap	Interest Paid InterestPaid	1973000	USD
CY2009	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.32
CY2009	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.33
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2009	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34118846	shares
CY2009	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33887766	shares
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40365215	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40365215	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47197572	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47197572	shares
CY2009	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2129000	USD
CY2009	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2179000	USD
CY2009	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000	USD
CY2009	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	21049000	USD
CY2009	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	454000	USD
CY2009	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	60806000	USD
CY2009	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	39303000	USD
CY2009	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26810000	USD
CY2009	snta	Increase Decrease In Collaboration Payable IncreaseDecreaseInCollaborationPayable	-6294000	USD
CY2009	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-115625000	USD
CY2009	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1663000	USD
CY2009	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	-10294000	USD
CY2009	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	626000	USD
CY2009	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	255000	USD
CY2009	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1088000	USD
CY2009	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-151000	USD
CY2009	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-16000000	USD
CY2009	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2463000	USD
CY2009	us-gaap	Share Based Compensation ShareBasedCompensation	4579000	USD
CY2010	us-gaap	Interest Paid InterestPaid	578000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44155000	USD
CY2010	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-12845000	USD
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1834000	USD
CY2010	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	15000000	USD
CY2010	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	23530000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19802000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	136000	USD
CY2010	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	17250000	USD
CY2010	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	36916000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-38199000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4647000	USD
CY2010	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-310000	USD
CY2010	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	412000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2032000	USD
CY2010	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12000	USD
CY2009	us-gaap	Interest Paid InterestPaid	312000	USD
CY2010	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	116000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1933000	USD
CY2011	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
CY2011	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
CY2011	dei	Document Type DocumentType	10-K
CY2011	dei	Document Period End Date DocumentPeriodEndDate	2011-12-31
CY2011	dei	Amendment Flag AmendmentFlag	false
CY2011	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2011	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2011	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2011	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2011Q2	dei	Entity Public Float EntityPublicFloat	144500004	USD
CY2012Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57624866	shares
CY2011	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
CY2011	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	4048000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1235000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	36736000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	201000	USD
CY2009	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	58000	USD
CY2011	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	378000	USD
CY2011	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2000000	USD
CY2011	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	27581000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9329000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	690000	USD
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	60745000	USD
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	50726000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-47300000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6731000	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	400000	USD
CY2011	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	330000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1542000	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	265000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	130000	USD
CY2011	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-116000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1464000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	3354000	USD
CY2008Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52045000	USD
CY2009	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-7890000	USD
CY2011	us-gaap	Nature Of Operations NatureOfOperations	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="FONT-FAMILY: times"><font size="2"><b>(1) Nature of Business </b></font></p> <p style="FONT-FAMILY: times"><font size="2">        Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. </font></p> <p style="FONT-FAMILY: times"><font size="2">        The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations. </font></p> <p style="FONT-FAMILY: times"><font size="2">        The Company has incurred significant operating losses since its inception and, as a result, at December 31, 2011 had an accumulated deficit of $398.4 million. Operations have been funded principally through the sale of common stock and convertible preferred stock, capital leases, non-refundable payments under the former collaboration agreements with GlaxoSmithKline (GSK) and Hoffman-La Roche (Roche), and proceeds from term loans by General Electric Capital Corporation (GECC) and Oxford Finance Corporation (Oxford) (see Note 11). At December 31, 2011, the Company had approximately $39.7 million in cash, cash equivalents and marketable securities. In January and February 2012, the Company raised approximately $33.0 million in net proceeds from the sale of 8,050,000 shares of its common stock in an underwritten public offering at a public offering price of $4.40 per share (see Note 15). </font></p> <p style="FONT-FAMILY: times"><font size="2">        Based on the Company's current operating levels, it expects its cash resources, including the $33.0 million in net proceeds raised in the public offering in January and February 2012, will be sufficient to fund operations into the first half of 2013. This estimate assumes that certain activities contemplated for 2012 will be conducted subject to the availability of sufficient financial resources. The Company expects to continue evaluating additional potential sources of funding, including partnership agreements, cost or risk-sharing agreements, equity financings or other sources. </font></p> <p style="FONT-FAMILY: times"><font size="2">        However, the Company may require significant additional funds earlier than it currently expects in order to conduct additional clinical trials and continue to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. </font></p></td></tr></table>
CY2011	snta	Proceeds From Stock Sale To Related Parties ProceedsFromStockSaleToRelatedParties	7734000	USD

Files In Submission

Name	View Source	Status
0001047469-12-001243-index-headers.html	Edgar Link	pending
0001047469-12-001243-index.html	Edgar Link	pending
0001047469-12-001243.txt	Edgar Link	pending
0001047469-12-001243-xbrl.zip	Edgar Link	pending
a2207421z10-k.htm	Edgar Link	pending
a2207421zex-10_64.htm	Edgar Link	pending
a2207421zex-23_1.htm	Edgar Link	pending
a2207421zex-31_1.htm	Edgar Link	pending
a2207421zex-31_2.htm	Edgar Link	pending
a2207421zex-32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g434273.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20111231.xml	Edgar Link	completed
snta-20111231.xsd	Edgar Link	pending
snta-20111231_cal.xml	Edgar Link	unprocessable
snta-20111231_def.xml	Edgar Link	unprocessable
snta-20111231_lab.xml	Edgar Link	unprocessable
snta-20111231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

2011 Form 10-K Financial Statement

#000104746912001243 Filed on February 22, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL Madrigal Pharmaceuticals Inc Stock $mdgl

2011 Form 10-K Financial Statement

#000104746912001243 Filed on February 22, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl